deltatrials
Completed PHASE2 INTERVENTIONAL 5-arm NCT04817670

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease (ViSionSerenity)

A Phase 2a, Double-blind, Randomised, Placebo-controlled, Efficacy, and Safety Study of Multiple Doses of VIT-2763 in Subjects With Sickle Cell Disease (ViSionSerenity)

Sponsor: Fortrea

Conditions Sickle Cell Disease
Interventions Placebo BID Placebo TID VIT-2763 120 mg VIT-2763 240 mg VIT-2763 360 mg
Updated 28 times since 2021 Last updated: Jan 27, 2025 Started: Nov 18, 2021 Primary completion: Mar 7, 2024 Completion: Mar 7, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Sickle Cell Disease and is currently completed. Fortrea leads this study, which shows 28 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~Apr 2024 · 3 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Mar 2025 · 5 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

28 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Oct 2024 — Mar 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

▶ Show 23 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE2

  2. May 2024 — Jun 2024 [monthly]

    Completed PHASE2

  3. Apr 2024 — May 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Jan 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  5. Oct 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  6. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  7. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  8. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  9. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  10. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  11. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  12. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  13. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  14. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  15. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  16. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Suspended → Active Not Recruiting

  17. Apr 2022 — Jul 2022 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  18. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  19. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  20. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  21. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  22. May 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

  23. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fortrea
  • Vifor (International) Inc.
Data source: Vifor Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Aurora, United States , Baabda, Lebanon , Beirut, Lebanon , Birmingham, United States , Charleston, United States , Chicago, United States , Colombes, France , Greenville, United States , Hollywood, United States and 8 more locations